MANE 8-K SEC Filing Analysis

Latest settled — T+5d

MANE ▼ -3.39% at T+5d

NEUTRAL call ✗ call lost -3.39% · α vs SPY -3.47% · entry $103.90 → $100.38

Next anchor: T+20d due 5d ago

Last close $96.07 (close Jun 12) · -7.54% from $103.90 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

+3.12%

call +3.12% · α +2.54%

$107.14

settled 5w ago

T+5d

-3.39%

call -3.39% · α -3.47%

$100.38

settled 27d ago

T+20d

—

call — · α —

—

due 5d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Veradermics reported Q1 2026 results showing a net loss of $27.2M, widening from a $12.4M loss in Q1 2025, driven by increased R&D and G&A expenses as the company advances its lead candidate VDPHL01. The company highlighted positive Phase 2/3 topline data from Study 302 and a strong cash position of $390.8M, with additional $472M raised post-quarter via a follow-on offering, extending runway into 2030.

Actionable Insight

Monitor upcoming Phase 3 data readouts from Study 304 and Study 306 in H2 2026, which are the next major catalysts. The strong cash runway into 2030 reduces near-term dilution risk, but the pre-revenue stage means stock movement will be driven entirely by clinical milestones.

Key Facts

Net loss of $27.2M for Q1 2026 vs $12.4M in Q1 2025
Cash, cash equivalents, and marketable securities of $390.8M as of March 31, 2026
Raised approximately $766.8M in aggregate gross proceeds in 2026 through IPO and follow-on offering
Positive topline results from Phase 2/3 Study 302 for VDPHL01 in April 2026
Enrollment completed in confirmatory Phase 3 Study 304; topline data expected H2 2026
R&D expenses increased to $20.9M from $11.4M YoY
G&A expenses increased to $8.9M from $1.5M YoY

Financial Impact

Net loss increased by $14.8M YoY; cash position strengthened by ~$249M from year-end 2025

net losscash positionR&D expensesG&A expenses

Risk Factors

No approved products or revenue; pre-revenue stage biotech risk
Clinical trial failure risk for VDPHL01 in ongoing Phase 3 studies
Dilution risk from future capital raises if cash runway needs extension

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001827635-26-000016
Document: mane-20260512.htm	0001827635-26-000016
Document: 0001827635-26-000016-index-headers.html	0001827635-26-000016
Document: 0001827635-26-000016-index.html	0001827635-26-000016
Document: 0001827635-26-000016.txt	0001827635-26-000016
8-K Data (Synthetic)	0001827635-26-000016

4 reports for MANE

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for MANE — sortable, filterable
	Type				Now
May 12, 2026 4w ago	8-K NEUTRAL ★ 5/10	$103.90 $100.38	▼ −3.39%	▼ −3.47%	$96.07 (−7.54%)
May 1, 2026 6w ago	8-K NEUTRAL ★ 5/10	$105.26 $108.13	▲ +2.73%	▼ −0.21%	$96.07 (−8.73%)
Apr 27, 2026 6w ago	8-K NEUTRAL ★ 3/10	$103.10 $105.26	▲ +2.10%	▲ +0.40%	$96.07 (−6.82%)
Apr 27, 2026 6w ago	8-K BULLISH ★ 7/10	$100.10 $105.26	▲ +5.15%	▲ +4.75%	$96.07 (−4.03%)

US Market Status

Market Closed — Opens in 3h 59m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access